RARE ULTRAGENYX PHARMACEUTICAL INC Product Launches 8-K Filing 2024 - FDA Application Ultragenyx Pharmaceutical Inc. submitted a Biologics License Application to the FDA for accelerated approval of UX111 gene therapy for Sanfilippo syndrome type A, supported by data showing improved cognitive development in patients.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC